Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses NBIX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NBIX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kyle Gano | $920,000 | $966,000 | $5,750,023 | $5,750,006 | $0 | $0 | $62,906 | $13,448,935 |
| Chief Executive Officer and Director | ||||||||
| Sanjay Keswani | 379,167 | 488,000 | 4,000,120 | 3,999,963 | 0 | 0 | 140,553 | 9,007,803 |
| Chief Medical Officer | ||||||||
| Jude Onyia | 720,520 | 645,000 | 2,999,925 | 3,000,011 | 0 | 0 | 45,313 | 7,410,769 |
| Chief Scientific Officer | ||||||||
| Matthew Abernethy | 725,913 | 526,000 | 2,499,918 | 2,500,036 | 0 | 0 | 60,045 | 6,311,912 |
| Chief Financial Officer | ||||||||
| Eiry Roberts | 731,400 | 530,000 | 2,375,004 | 2,375,029 | 0 | 0 | 61,599 | 6,073,032 |
| Strategic Advisor | ||||||||
| Eric Benevich | 668,690 | 463,000 | 2,349,928 | 2,349,995 | 0 | 0 | 57,334 | 5,888,947 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kyle Gano | $13,448,935 | — | — | — |
| Sanjay Keswani | 9,007,803 | — | — | — |
| Jude Onyia | 7,410,769 | 7,035,851 | 7,223,216 | +374,918 |
| Matthew Abernethy | 6,311,912 | — | — | — |
| Eiry Roberts | 6,073,032 | — | — | — |
| Eric Benevich | 5,888,947 | 6,306,164 | — | −417,217 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Leslie V. Norwalk | Director | 2026-05-12 | D | 3,810 | $155 | $590,601 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 158 | 2,364,761 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | A | 15,000 | 48 | 718,350 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | A | 205,088 | 43 | 8,868,005 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 205,088 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 245,088 | 154 | 37,824,872 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-21 | — | 4,977 | — | — | 3 insiders, 3 accrual rows | ||
| William H. Rastetter | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-05-26 | D | 3,888 | 157 | 609,023 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-27 | — | 2,568 | — | — | 2 insiders, 2 accrual rows | ||
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 156 | 1,710,865 | Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-27 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | A | 2,261 | 79 | 178,664 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 157 | 354,321 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 160 | 1,762,710 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 3,520 | 159 | 558,236 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 3,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 9,521 | 158 | 1,500,663 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | A | 24,965 | 81 | 2,034,398 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 4,216 | 157 | 660,925 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 14,214 | 155 | 2,200,685 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 5,466 | 155 | 849,726 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 1,733 | 155 | 268,338 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | A | 3,212 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 24,965 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-06-04 | D | 1,250 | 168 | 210,072 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 15,000 | 54 | 804,600 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 1,843 | 167 | 308,357 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 5,829 | 167 | 970,859 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 6,896 | 166 | 1,143,306 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 2,549 | 164 | 419,156 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 10,000 | 80 | 797,900 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 7,883 | 164 | 1,291,291 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-05 | D | 2,441 | 0 | 0 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 1,690 | 81 | 137,718 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 8,110 | 81 | 660,884 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 200 | 81 | 16,298 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-26 | — | 1,890 | — | — | 1 insider, 2 accrual rows | ||
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 1,690 | 171 | 288,676 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 8,110 | 170 | 1,378,903 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 200 | 170 | 33,913 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 8,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 8,433 | 104 | 872,984 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 3,401 | 104 | 352,072 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 2,737 | 179 | 488,672 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 8,433 | 179 | 1,507,135 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 2,737 | 104 | 283,334 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 179 | 607,305 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 8,433 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 2,737 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | A | 10,000 | 81 | 814,900 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 180 | 1,796,014 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 181 | 790,514 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | A | 4,367 | 106 | 462,989 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-28 | A | 842 | 139 | 117,400 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-28 | — | 842 | — | — | 1 insider, 1 accrual row | ||
| Leslie V. Norwalk | Director | 2026-07-28 | D | 1,250 | 182 | 227,508 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Leslie V. Norwalk | Director | 2026-05-12 | D | 3,810 | $155 | $590,601 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 158 | 2,364,761 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | A | 15,000 | 48 | 718,350 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | A | 205,088 | 43 | 8,868,005 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 205,088 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 245,088 | 154 | 37,824,872 | Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-21 | D | 1,659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-21 | D | 1,659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-21 | D | 1,659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-05-26 | D | 3,888 | 157 | 609,023 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-27 | A | 1,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 156 | 1,710,865 | Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-27 | A | 1,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-27 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | A | 2,261 | 79 | 178,664 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 157 | 354,321 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 160 | 1,762,710 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 3,520 | 159 | 558,236 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 3,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 9,521 | 158 | 1,500,663 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | A | 24,965 | 81 | 2,034,398 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 4,216 | 157 | 660,925 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 14,214 | 155 | 2,200,685 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 5,466 | 155 | 849,726 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 1,733 | 155 | 268,338 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | A | 3,212 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 24,965 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-06-04 | D | 1,250 | 168 | 210,072 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 15,000 | 54 | 804,600 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 1,843 | 167 | 308,357 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 5,829 | 167 | 970,859 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 6,896 | 166 | 1,143,306 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 2,549 | 164 | 419,156 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 10,000 | 80 | 797,900 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 7,883 | 164 | 1,291,291 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-05 | D | 2,441 | 0 | 0 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 1,690 | 81 | 137,718 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 8,110 | 81 | 660,884 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 200 | 81 | 16,298 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 1,690 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 1,690 | 171 | 288,676 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 8,110 | 170 | 1,378,903 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 200 | 170 | 33,913 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 8,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 8,433 | 104 | 872,984 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 3,401 | 104 | 352,072 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 2,737 | 179 | 488,672 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 8,433 | 179 | 1,507,135 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 2,737 | 104 | 283,334 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 179 | 607,305 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 8,433 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 2,737 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | A | 10,000 | 81 | 814,900 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 180 | 1,796,014 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 181 | 790,514 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | A | 4,367 | 106 | 462,989 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-28 | A | 842 | 139 | 117,400 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-28 | D | 842 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-28 | D | 1,250 | 182 | 227,508 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kyle Gano | OPTION | 2025-01-30 | — | — | 104,736 | — | $5,750,006 |
| Matthew Abernethy | OPTION | 2025-01-30 | — | — | 45,538 | — | 2,500,036 |
| Eric Benevich | OPTION | 2025-01-30 | — | — | 42,805 | — | 2,349,995 |
| Jude Onyia | OPTION | 2025-01-30 | — | — | 54,645 | — | 3,000,011 |
| Eric Benevich | RSU | 2025-01-30 | — | — | 8,022 | — | 940,018 |
| Jude Onyia | RSU | 2025-01-30 | — | — | 10,241 | — | 1,200,040 |
| Kyle Gano | PSU | 2025-01-30 | 29,442 | 44,162 | — | 58,884 | 3,450,014 |
| Eiry Roberts | RSU | 2025-01-30 | — | — | 8,108 | — | 950,095 |
| Eiry Roberts | OPTION | 2025-01-30 | — | — | 43,261 | — | 2,375,029 |
| Sanjay Keswani | PSU | 2025-03-06 | 6,262 | 7,828 | — | 9,785 | 975,056 |
| Sanjay Keswani | PSU | 2025-03-06 | 11,440 | 17,160 | — | 22,880 | 1,424,966 |
| Matthew Abernethy | RSU | 2025-01-30 | — | — | 8,534 | — | 1,000,014 |
| Matthew Abernethy | PSU | 2025-01-30 | 12,800 | 19,202 | — | 25,602 | 1,499,904 |
| Sanjay Keswani | RSU | 2025-03-06 | — | — | 12,846 | — | 1,600,098 |
| Eric Benevich | PSU | 2025-01-30 | 12,032 | 18,050 | — | 24,066 | 1,409,910 |
| Kyle Gano | RSU | 2025-01-30 | — | — | 19,628 | — | 2,300,009 |
| Eiry Roberts | PSU | 2025-01-30 | 12,160 | 18,242 | — | 24,322 | 1,424,909 |
| Jude Onyia | PSU | 2025-01-30 | 15,360 | 23,042 | — | 30,722 | 1,799,885 |
| Sanjay Keswani | OPTION | 2025-03-06 | — | — | 70,101 | — | 3,999,963 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kyle Gano | $2,300,009 | $3,450,014 | $5,750,006 | 30.0% |
| Matthew Abernethy | 1,000,014 | 1,499,904 | 2,500,036 | 30.0% |
| Eric Benevich | 940,018 | 1,409,910 | 2,349,995 | 30.0% |
| Jude Onyia | 1,200,040 | 1,799,885 | 3,000,011 | 30.0% |
| Eiry Roberts | 950,095 | 1,424,909 | 2,375,029 | 30.0% |
| Sanjay Keswani | 1,600,098 | 2,400,022 | 3,999,963 | 30.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Eiry Roberts | RSU | 4,115 | — | $583,630 |
| Jude Onyia | Option | 29,287 | 133.84 | — |
| Eiry Roberts | RSU | 16,613 | — | 2,356,222 |
| Kyle Gano | RSU | 12,550 | — | 1,779,967 |
| Kyle Gano | RSU | 9,968 | — | 1,413,761 |
| Kyle Gano | RSU | 6,725 | — | 953,807 |
| Matthew Abernethy | RSU | 6,725 | — | 953,807 |
| Eric Benevich | RSU | 4,166 | — | 590,864 |
| Matthew Abernethy | Option | 18,605 | 103.52 | — |
| Eiry Roberts | RSU | 2,769 | — | 392,727 |
| Sanjay Keswani | PSU | 7,828 | — | 1,110,245 |
| Kyle Gano | RSU | 5,132 | — | 727,872 |
| Matthew Abernethy | RSU | 5,132 | — | 727,872 |
| Eiry Roberts | RSU | 4,227 | — | 599,515 |
| Sanjay Keswani | Option | 70,101 | 124.56 | — |
| Jude Onyia | Option | 43,261 | 117.18 | — |
| Eiry Roberts | Option | 34,248 | 117.18 | — |
| Jude Onyia | Option | 19,699 | 103.52 | — |
| Kyle Gano | Option | 24,406 | 133.84 | — |
| Eiry Roberts | Option | 1,571 | 79.02 | — |
| Eric Benevich | RSU | 5,885 | — | 834,670 |
| Kyle Gano | PSU | 29,442 | — | 4,175,759 |
| Kyle Gano | RSU | 19,628 | — | 2,783,839 |
| Jude Onyia | PSU | 15,361 | — | 2,178,651 |
| Sanjay Keswani | RSU | 12,846 | — | 1,821,948 |
| Eric Benevich | PSU | 12,033 | — | 1,706,641 |
| Sanjay Keswani | RSU | 11,441 | — | 1,622,677 |
| Jude Onyia | RSU | 10,241 | — | 1,452,481 |
| Matthew Abernethy | RSU | 8,534 | — | 1,210,377 |
| Eiry Roberts | RSU | 8,108 | — | 1,149,958 |
| Eric Benevich | RSU | 8,022 | — | 1,137,760 |
| Eric Benevich | Option | 15,103 | 103.52 | — |
| Kyle Gano | PSU | 3,683 | — | 522,360 |
| Eiry Roberts | Option | 12,203 | 133.84 | — |
| Matthew Abernethy | RSU | 2,437 | — | 345,640 |
| Kyle Gano | Option | 82,916 | 117.18 | — |
| Matthew Abernethy | RSU | 10,040 | — | 1,423,973 |
| Kyle Gano | RSU | 2,927 | — | 415,136 |
| Jude Onyia | RSU | 238 | — | 33,756 |
| Jude Onyia | Option | 135 | 79.02 | — |
| Eric Benevich | Option | 33,887 | 117.18 | — |
| Eric Benevich | RSU | 16,613 | — | 2,356,222 |
| Kyle Gano | Option | 1,661 | 79.02 | — |
| Jude Onyia | RSU | 8,070 | — | 1,144,568 |
| Matthew Abernethy | RSU | 9,968 | — | 1,413,761 |
| Eric Benevich | RSU | 12,550 | — | 1,779,967 |
| Kyle Gano | Option | 18,605 | 103.52 | — |
| Jude Onyia | RSU | 7,172 | — | 1,017,205 |
| Matthew Abernethy | Option | 24,406 | 133.84 | — |
| Eiry Roberts | RSU | 7,172 | — | 1,017,205 |
| Kyle Gano | RSU | 1,842 | — | 261,251 |
| Matthew Abernethy | Option | 1,383 | 79.02 | — |
| Eric Benevich | Option | 1,302 | 79.02 | — |
| Jude Onyia | RSU | 19,935 | — | 2,827,381 |
| Matthew Abernethy | PSU | 12,801 | — | 1,815,566 |
| Eiry Roberts | PSU | 12,161 | — | 1,724,795 |
| Matthew Abernethy | Option | 36,051 | 117.18 | — |
| Eiry Roberts | Option | 15,322 | 103.52 | — |
| Jude Onyia | RSU | 5,434 | — | 770,704 |
| Eric Benevich | Option | 21,356 | 133.84 | — |
| Eiry Roberts | RSU | 3,363 | — | 476,974 |
| Kyle Gano | Option | 9,730 | 122.21 | — |
| Eiry Roberts | Option | 15,042 | 136.69 | — |
| Eric Benevich | RSU | 2,294 | — | 325,358 |
We believe that in order to create value for our stockholders, it is critical to attract, motivate and retain key executive officer talent by providing competitive compensation packages. Our compensation philosophy for executive officers provides that cash compensation should be structured such that at least one-third of each executive officer's target total cash compensation, consisting of base salary and target cash incentives, is at risk and dependent upon the Company's achievement of specific corporate goals that drive stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-27 | 78,993,894 | 5,669,155 | 103,231 | 93.19% | Passed |
| 2025 | 2025-05-21 | 77,981,925 | 6,070,336 | 1,676,512 | 90.96% | Passed |
| 2024 | 2024-05-22 | 80,281,842 | 4,276,395 | 1,106,972 | 93.72% | Passed |
| 2023 | 2023-05-17 | 75,903,905 | 5,557,583 | 61,094 | 93.11% | Passed |
| 2022 | 2022-05-18 | 76,665,649 | 5,934,421 | 43,078 | 92.77% | Passed |
| 2021 | 2021-05-19 | 77,232,378 | 2,952,915 | 95,463 | 96.2% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-27 | 93.19%a |
| 2025 | 2025-05-21 | 90.96%b |
| 2024 | 2024-05-22 | 93.72%c |
a. Approved under the standard stated in the filing — “Accordingly, an abstention will have the effect of a negative vote for each item.”.
b. Approved under the standard stated in the filing — “Accordingly, an abstention will have the effect of a negative vote for each item.”.
c. Approved under the standard stated in the filing — “Accordingly, an abstention will have the effect of a negative vote for each item.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 49 : 1 |
|---|---|
| CEO total compensation | $13,448,935 |
| Median employee compensation | $273,341 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William H. RastetterIndependent · Board Chair · Science and Medical Technology · Not standing for re-election | $105,000 | $400,018 | — | $0 | $0 | $505,018 |
| Shalini SharpIndependent · Audit (Chair) · Compensation · Not standing for re-election | 100,250 | 200,009 | 200,019 | 0 | 0 | 500,278 |
| Stephen A. SherwinIndependent · Audit · Science and Medical Technology (Chair) · Not standing for re-election | 93,250 | 400,018 | — | 0 | 0 | 493,268 |
| Richard F. PopsIndependent · Compensation (Chair) · Nominating/Corporate Governance · Science and Medical Technology · Not standing for re-election | 87,750 | 400,018 | — | 0 | 0 | 487,768 |
| Christine A. PoonIndependent · Audit · Nominating/Corporate Governance · Not standing for re-election | 83,750 | 400,018 | — | 0 | 0 | 483,768 |
| George J. MorrowIndependent · Compensation · Nominating/Corporate Governance · Not standing for re-election | 81,000 | 400,018 | — | 0 | 0 | 481,018 |
| Leslie V. NorwalkIndependent · Nominating/Corporate Governance (Chair) · Not standing for re-election | 78,000 | 200,009 | 200,019 | 0 | 0 | 478,028 |
| Kevin C. GormanNot independent · Science and Medical Technology | 70,000 | — | 400,037 | 0 | 0 | 470,037 |
| Gary A. LyonsIndependent · Science and Medical Technology | 70,000 | 200,009 | 200,019 | 0 | 0 | 470,028 |
| Johanna MercierIndependent · Nominating/Corporate Governance | 69,000 | 400,018 | — | 0 | 0 | 469,018 |
| Kyle W. GanoEmployee director · Not standing for re-election | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $100,000 |
|---|---|
| Annual equity retainer | $400,018 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 18,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $838,000 |
| Equity awards (grant-date value) | $3,000,135 |
| All other compensation | $0 |
| Total cost of the board | $3,838,135 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Neurocrine BioSciences Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Neurocrine BioSciences Inc.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 4 | Biomarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 5 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 6 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 7 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 8 | BeOne Medicines Ltd. | 2025 | John Oyler | 1,133,000 | 11,249,615 | 3,749,967 | 1,676,840 | 17,943,521 |
| 9 | Organon & Co. | 2025 | Kevin Ali | 1,088,462 | 10,251,989 | 3,249,999 | 0 | 15,813,296 |
| 10 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 11 | Neurocrine BioSciences Inc | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 12 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 13 | Ultragenyx Pharmaceutical Inc | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 14 | ACADIA Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 15 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| — | argenx SE | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Neurocrine BioSciences Inc | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| ACADIA Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Alkermes plc | 130% | PSU 53 · RSU 24 · Options 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
| argenx SE | not disclosed | not disclosed | not disclosed | not disclosed |
| BeOne Medicines Ltd. | 148% | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| Biomarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Incyte Corporation | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals, Inc. | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Organon & Co. | 72% | PSU 50 · RSU 25 · Options 25 | Yes — Three-Year Relative TSR | Korn Ferry |
| Sarepta Therapeutics, Inc. | 100% | RSU 50 · PSU 50 | No | FW Cook |
| Ultragenyx Pharmaceutical Inc | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics Corporation | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kyle Gano | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 2 | Section 01, Sanjay Keswani | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 9,007,803. Filing ↗machine: t50 · r10 · c7 · span 859729–859738 |
| 3 | Section 01, Jude Onyia | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 7,410,769. Filing ↗machine: t50 · r14 · c7 · span 866156–866165 |
| 4 | Section 01, Matthew Abernethy | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 6,311,912. Filing ↗machine: t50 · r7 · c7 · span 853754–853763 |
| 5 | Section 01, Eiry Roberts | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 6,073,032. Filing ↗ |
| 6 | Section 01, Eric Benevich | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 5,888,947. Filing ↗machine: t50 · r9 · c7 · span 857757–857766 |
| 7 | Section 03, Kyle Gano OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r5 · c8 · span 905774–905781 |
| 8 | Section 03, Matthew Abernethy OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r8 · c8 · span 910632–910638 |
| 9 | Section 03, Eric Benevich OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r5 · c6 · span 778763–778769 |
| 10 | Section 03, Jude Onyia OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r6 · c6 · span 782401–782407 |
| 11 | Section 03, Eric Benevich RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r5 · c12 · span 779670–779675 |
| 12 | Section 03, Jude Onyia RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r6 · c12 · span 783310–783316 |
| 13 | Section 03, Kyle Gano PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r4 · c7 · span 903792–903798 |
| 14 | Section 03, Eiry Roberts RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r19 · c7 · span 930385–930390 |
| 15 | Section 03, Eiry Roberts OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r21 · c8 · span 933609–933615 |
| 16 | Section 03, Sanjay Keswani PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r15 · c5 · span 922606–922611 |
| 17 | Section 03, Sanjay Keswani PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r13 · c7 · span 919546–919552 |
| 18 | Section 03, Matthew Abernethy RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r6 · c7 · span 907406–907411 |
| 19 | Section 03, Matthew Abernethy PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r7 · c7 · span 909050–909056 |
| 20 | Section 03, Sanjay Keswani RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r12 · c7 · span 917903–917909 |
| 21 | Section 03, Eric Benevich PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r10 · c7 · span 914298–914304 |
| 22 | Section 03, Kyle Gano RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r3 · c7 · span 901742–901748 |
| 23 | Section 03, Eiry Roberts PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r20 · c7 · span 932027–932033 |
| 24 | Section 03, Jude Onyia PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r17 · c7 · span 926772–926778 |
| 25 | Section 03, Sanjay Keswani OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r14 · c8 · span 921126–921132 |
| 26 | Section 07, pay ratio | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “CEO Pay Ratio”. As printed: 49 : 1. Filing ↗machine: span 1221176–1221183 |
| 27 | Section 08, William H. Rastetter | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 505,018. Filing ↗machine: t70 · r2 · c8 · span 1313093–1313101 |
| 28 | Section 08, Shalini Sharp | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 500,278. Filing ↗machine: t70 · r10 · c8 · span 1325253–1325261 |
| 29 | Section 08, Stephen A. Sherwin | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 493,268. Filing ↗machine: t70 · r11 · c8 · span 1326781–1326789 |
| 30 | Section 08, Richard F. Pops | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 487,768. Filing ↗machine: t70 · r9 · c8 · span 1323739–1323747 |
| 31 | Section 08, Christine A. Poon | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 483,768. Filing ↗machine: t70 · r8 · c8 · span 1322225–1322233 |
| 32 | Section 08, George J. Morrow | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 481,018. Filing ↗machine: t70 · r6 · c8 · span 1319163–1319171 |
| 33 | Section 08, Leslie V. Norwalk | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 478,028. Filing ↗machine: t70 · r7 · c8 · span 1320680–1320688 |
| 34 | Section 08, Kevin C. Gorman | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 470,037. Filing ↗machine: t70 · r3 · c8 · span 1314624–1314632 |
| 35 | Section 08, Gary A. Lyons | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 470,028. Filing ↗machine: t70 · r4 · c8 · span 1316136–1316144 |
| 36 | Section 08, Johanna Mercier | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 469,018. Filing ↗machine: t70 · r5 · c8 · span 1317649–1317657 |
| 37 | Section 08, Kyle W. Gano | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 38 | Section 02, Leslie V. Norwalk 2026-05-12 | Form 4 | 2026-05-14 | 0001533568-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Richard F. Pops 2026-05-15 | Form 4 | 2026-05-18 | 0000914475-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Richard F. Pops 2026-05-15 | Form 4 | 2026-05-18 | 0000914475-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Richard F. Pops 2026-05-15 | Form 4 | 2026-05-18 | 0000914475-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Kevin C. Gorman 2026-05-19 | Form 4 | 2026-05-21 | 0001201096-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Kevin C. Gorman 2026-05-19 | Form 4 | 2026-05-21 | 0001201096-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Kevin C. Gorman 2026-05-19 | Form 4 | 2026-05-21 | 0001201096-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Shalini Sharp 2026-05-21 | Form 4 | 2026-05-21 | 0001377202-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, William H. Rastetter 2026-05-21 | Form 4 | 2026-05-21 | 0001205903-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Leslie V. Norwalk 2026-05-21 | Form 4 | 2026-05-21 | 0001533568-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Christine A. Poon 2026-05-21 | Form 4 | 2026-05-21 | 0001189014-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, George J. Morrow 2026-05-21 | Form 4 | 2026-05-21 | 0001068754-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Johanna Mercier 2026-05-21 | Form 4 | 2026-05-21 | 0001782135-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Johanna Mercier 2026-05-21 | Form 4 | 2026-05-21 | 0001782135-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, George J. Morrow 2026-05-21 | Form 4 | 2026-05-21 | 0001068754-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Stephen A. Sherwin 2026-05-21 | Form 4 | 2026-05-21 | 0001079462-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Stephen A. Sherwin 2026-05-21 | Form 4 | 2026-05-21 | 0001079462-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Gary A. Lyons 2026-05-21 | Form 4 | 2026-05-21 | 0001123343-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Gary A. Lyons 2026-05-21 | Form 4 | 2026-05-21 | 0001123343-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Leslie V. Norwalk 2026-05-21 | Form 4 | 2026-05-21 | 0001533568-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Christine A. Poon 2026-05-21 | Form 4 | 2026-05-21 | 0001189014-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Richard F. Pops 2026-05-21 | Form 4 | 2026-05-21 | 0001126490-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Shalini Sharp 2026-05-21 | Form 4 | 2026-05-21 | 0001377202-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Richard F. Pops 2026-05-21 | Form 4 | 2026-05-21 | 0001126490-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, William H. Rastetter 2026-05-21 | Form 4 | 2026-05-21 | 0001205903-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, David W. Boyer 2026-05-26 | Form 4 | 2026-05-28 | 0001909817-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Richard F. Pops 2026-05-27 | Form 4 | 2026-05-29 | 0001126490-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Jude Onyia 2026-05-27 | Form 4 | 2026-05-29 | 0001894425-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, George J. Morrow 2026-05-27 | Form 4 | 2026-05-29 | 0001068754-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Leslie V. Norwalk 2026-05-27 | Form 4 | 2026-05-29 | 0001533568-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Jude Onyia 2026-05-27 | Form 4 | 2026-05-29 | 0001894425-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Johanna Mercier 2026-05-27 | Form 4 | 2026-05-29 | 0001782135-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Gary A. Lyons 2026-05-27 | Form 4 | 2026-05-29 | 0001123343-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Gary A. Lyons 2026-05-27 | Form 4 | 2026-05-29 | 0001123343-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Kevin C. Gorman 2026-05-27 | Form 4 | 2026-05-29 | 0001201096-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Shalini Sharp 2026-05-27 | Form 4 | 2026-05-29 | 0001377202-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Christine A. Poon 2026-05-27 | Form 4 | 2026-05-29 | 0001189014-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Jude Onyia 2026-05-27 | Form 4 | 2026-05-29 | 0001894425-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Leslie V. Norwalk 2026-05-27 | Form 4 | 2026-05-29 | 0001533568-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, William H. Rastetter 2026-05-27 | Form 4 | 2026-05-29 | 0001205903-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Stephen A. Sherwin 2026-05-27 | Form 4 | 2026-05-29 | 0001079462-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Ingrid Delaet 2026-05-29 | Form 4 | 2026-06-02 | 0001965808-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Ingrid Delaet 2026-05-29 | Form 4 | 2026-06-02 | 0001965808-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Ingrid Delaet 2026-05-29 | Form 4 | 2026-06-02 | 0001965808-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Jude Onyia 2026-06-01 | Form 4 | 2026-06-02 | 0001894425-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Jude Onyia 2026-06-01 | Form 4 | 2026-06-02 | 0001894425-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Jude Onyia 2026-06-01 | Form 4 | 2026-06-02 | 0001894425-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Sanjay Keswani 2026-06-02 | Form 4 | 2026-06-04 | 0001818524-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Sanjay Keswani 2026-06-02 | Form 4 | 2026-06-04 | 0001818524-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Sanjay Keswani 2026-06-02 | Form 4 | 2026-06-04 | 0001818524-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Leslie V. Norwalk 2026-06-04 | Form 4 | 2026-06-08 | 0001533568-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Jude Onyia 2026-06-05 | Form 4 | 2026-06-09 | 0001894425-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Darin Lippoldt 2026-07-09 | Form 4 | 2026-07-13 | 0001504783-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Darin Lippoldt 2026-07-09 | Form 4 | 2026-07-13 | 0001504783-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Darin Lippoldt 2026-07-09 | Form 4 | 2026-07-13 | 0001504783-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Ingrid Delaet 2026-07-10 | Form 4 | 2026-07-13 | 0001965808-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Ingrid Delaet 2026-07-10 | Form 4 | 2026-07-13 | 0001965808-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Ingrid Delaet 2026-07-10 | Form 4 | 2026-07-13 | 0001965808-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Leslie V. Norwalk 2026-07-28 | Form 4 | 2026-07-30 | 0001533568-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Leslie V. Norwalk 2026-07-28 | Form 4 | 2026-07-30 | 0001533568-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Leslie V. Norwalk 2026-07-28 | Form 4 | 2026-07-30 | 0001533568-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 06, 2026 vote | Form 8-K | 2026-05-28 | 0000914475-26-000029 | Item 5.07 · say-on-pay result. As reported: 93.19% (votes for as printed: 78,993,894). Filing ↗ |
| 134 | Section 06, 2025 vote | Form 8-K | 2025-05-22 | 0000914475-25-000120 | Item 5.07 · say-on-pay result. As reported: 90.96% (votes for as printed: 77,981,925). Filing ↗ |
| 135 | Section 06, 2024 vote | Form 8-K | 2024-05-23 | 0000914475-24-000140 | Item 5.07 · say-on-pay result. As reported: 93.72% (votes for as printed: 80,281,842). Filing ↗ |
| 136 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 137 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 138 | Section 09b board cost (computed) | Computed | — | computed | Cash 838,000 + equity 3,000,135 + all other 0 = 3,838,135, summed across the director compensation table rows.machine: formula: Σ = 3,838,135 |
| 139 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 140 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 141 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 142 | Biomarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in Biomarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 143 | Moderna, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 144 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 145 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 146 | BeOne Medicines Ltd., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-049655 | CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021 |
| 147 | Organon & Co., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177411 | CEO total compensation as printed in Organon & Co.'s own proxy. As printed: 15,813,296. Filing ↗machine: r30 · c18 · span 3922588–3922598 |
| 148 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 149 | Neurocrine BioSciences Inc (subject), Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine BioSciences Inc's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 150 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 151 | Ultragenyx Pharmaceutical Inc, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 152 | ACADIA Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 153 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 154 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 155 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 156 | Section 10a, Organon & Co. reciprocity | DEF 14A | — | 0001193125-26-177411 | Organon & Co.'s most recent proxy was read; its disclosed peer group does not include Neurocrine BioSciences Inc. Filing ↗ |
| 157 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 158 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 159 | Section 10a, Moderna, Inc. reciprocity | DEF 14A | — | 0001308179-26-000081 | Moderna, Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 160 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 161 | Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals, Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 162 | Section 10a, Biomarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | Biomarin Pharmaceutical Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 163 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 164 | Section 10a, BeOne Medicines Ltd. reciprocity | DEF 14A | — | 0001104659-26-049655 | BeOne Medicines Ltd. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 165 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc. names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 166 | Section 10a, Ultragenyx Pharmaceutical Inc reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc names Neurocrine BioSciences Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |